Inclusion Criteria:  Subjects aged 18 years or over. Eligible for care by one of the four HAH structures in accordance with HAS criteria, With relapsed or refractory multiple myeloma (having received at least one previous treatment), Whose case has been examined at multidisciplinary team (MDT) meetings at Limoges University Hospital Centre, Receiving carfilzomib parenteral chemotherapy outsourced to an HAH setting (all patients receive the entire first cycle of carfilzomib and the 1st day of each of the subsequent cycles in an outpatient clinic). Having read the information leaflet concerning the Carfil-HAD study, Not objecting to the use of their data in the context of this study.  Exclusion Criteria:  Inability to understand the protocol or complete the questionnaires. Refusing to complete the questionnaires.